147 related articles for article (PubMed ID: 19250435)
1. Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis.
Abbasi NR; Orlow SJ
Pediatr Dermatol; 2009; 26(1):118. PubMed ID: 19250435
[TBL] [Abstract][Full Text] [Related]
2. Onset of lichen planopilaris during treatment with etanercept.
Garcovich S; Manco S; Zampetti A; Amerio P; Garcovich A
Br J Dermatol; 2008 May; 158(5):1161-3. PubMed ID: 18363764
[No Abstract] [Full Text] [Related]
3. Onset of lichen planus during treatment with etanercept.
Musumeci ML; Lacarrubba F; Micali G
Am J Clin Dermatol; 2010; 11 Suppl 1():55-6. PubMed ID: 20586513
[TBL] [Abstract][Full Text] [Related]
4. Subgroup analyses of etanercept in pediatric patients with psoriasis.
Paller AS; Eichenfield LF; Langley RG; Leonardi CL; Siegfried EC; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Aug; 63(2):e38-41. PubMed ID: 20633781
[No Abstract] [Full Text] [Related]
5. Multiple lentigines arising in resolving psoriatic plaques after treatment with etanercept.
Costa LA; Belinchón I; Betlloch I; Pérez-Crespo M; Mataix J
Dermatol Online J; 2008 Jan; 14(1):11. PubMed ID: 18319028
[TBL] [Abstract][Full Text] [Related]
6. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
7. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis.
Safa G; Loppin M; Bousser AM; Barbarot S
J Am Acad Dermatol; 2007 Feb; 56(2 Suppl):S19-20. PubMed ID: 17097376
[No Abstract] [Full Text] [Related]
8. Suspected rapid-onset neutropenia following etanercept use: disproved following rechallenge and lessons to be learned.
Sachdev A; Shwayder T
Int J Dermatol; 2013 Oct; 52(10):1287-8. PubMed ID: 22417135
[No Abstract] [Full Text] [Related]
9. Etanercept use for psoriasis in Taiwan: a case series study.
Chiu HY; Wang TS; Cho YT; Tsai TF
Int J Dermatol; 2013 Jun; 52(6):673-80. PubMed ID: 22348620
[TBL] [Abstract][Full Text] [Related]
10. Tinea versicolor associated with etanercept therapy.
Levy MS; Polsky D; Davidson A; Strober BE
J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S99-100. PubMed ID: 18489062
[No Abstract] [Full Text] [Related]
11. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.
Babino G; Esposito M; Mazzotta A; Chimenti S; Giunta A
Acta Derm Venereol; 2013 May; 93(3):373-4. PubMed ID: 23147755
[No Abstract] [Full Text] [Related]
12. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
Yamauchi PS; Lowe NJ
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
[No Abstract] [Full Text] [Related]
13. [Neutropenia and thrombocytopenia in a patient presenting psoriasis treated with etanercept].
Lahbabi I; Adamski H; Le Jean S; Cannieux V; Polard E; Chevrant-Breton J
Ann Dermatol Venereol; 2008 May; 135(5):409-10. PubMed ID: 18457732
[No Abstract] [Full Text] [Related]
14. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis.
Bachmeyer C; Thiolière B; Khosrotehrani K; Cattan E
J Am Acad Dermatol; 2007 Jan; 56(1):169-70. PubMed ID: 17190640
[No Abstract] [Full Text] [Related]
15. Lichen planus associated with etanercept.
Battistella M; Rivet J; Bachelez H; Lioté F
Br J Dermatol; 2008 Jan; 158(1):188-90. PubMed ID: 17944978
[No Abstract] [Full Text] [Related]
16. Etanercept: efficacy and safety.
Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
[TBL] [Abstract][Full Text] [Related]
17. Etanercept and infections.
Bertouch J
Br J Dermatol; 2009 Nov; 161(5):1209-10; author reply 1210-1. PubMed ID: 19754864
[No Abstract] [Full Text] [Related]
18. Etanercept therapy and acute myeloid leukemia.
Bachmeyer C
Am J Hematol; 2008 Apr; 83(4):345; author reply 345. PubMed ID: 18318433
[No Abstract] [Full Text] [Related]
19. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
[No Abstract] [Full Text] [Related]
20. Disseminated superficial porokeratosis secondary to immunosuppression induced by etanercept for extensive psoriasis.
Stewart L; Howat A; Coulson I
Arch Dermatol; 2010 Oct; 146(10):1193-4. PubMed ID: 20956674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
